PREIMUShchESTVA METFORMINA PROLONGIROVANNOGO DEYSTVIYa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data on the properties and effects of metformin - antihyperglycemic drug for first-line treatment of type 2 diabetes mellitus. So far, the use of metformin was limited to the development of side effects from the gastrointestinal tract and the large number of intakes of required dose of the drug, but introduction of long-acting form of metformin, Glucophage Long, allows to resolve the this problem.

Full Text

Restricted Access

References

  1. Evans JL, Goldfine ID, Maddux BA, et al. Are OxidativeStress-Activated Signaling Pathways Mediatorsof Insulin Resistance and β-Cell Dysfunction? Diabetes 2003;52:1-8.
  2. Bock G, Chittilapilly E, Basu R, et al. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose. Roleofincreasedratesofgluconeogenesis. Diabetes 2007;56:1703-10.
  3. Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med 2012;124(6):82-9.
  4. Шестакова М.В., Мкртумян А.М., Ярек-Мартынова И.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск) //Сахарный диабет 2011(3, приложение 1):4-72.
  5. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2.J ClinEndocrinolMetab2003;88:1323-32.
  6. Ferner RE, Rawlins M, Alberti KG. Impaired β-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes. Q J Med 1992; 66:137-46.
  7. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13(6): 696-704.
  8. Genuth S. The UKPDS and its global impact. Diabet Med 2008;25(2):57-62.
  9. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004;256:1-14.
  10. Patane G, Piro S, Rabuazzo AM, Anello M, et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2001;49(5):735-40.
  11. McFarlane SI, Banerij M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-18.
  12. Мкртумян А.М., Бирюкова Е.В. Метформин -единственный бигуанид с широким спектром действия, рекомендованный IDF как препарат первого ряда выбора // РМЖ 2006. Т. 14. № 27. С. 1991-96.
  13. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An Update. Ann Intern Med 2002;137:25-33.
  14. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011;54:339-49.
  15. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002;298:779-84.
  16. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2202;17:336-42.
  17. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152(12):4610-19.
  18. Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-7.
  19. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Vasc Dis 2001;1:28-32.
  20. Reasner CA, Burkhard G. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br J Vasc Dis 2002;2:460-67.Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103(6):491-97.
  21. De Fronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of Metformin in Patients with Non-InsulinDependent Diabetes Mellitus. N Engl J Med 1995;333:541-49.
  22. Blonde L, Dailey GE, Jabbour SA, Reasner et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediaterelease metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20(4):565-72.
  23. Fujioka K, Brazg RL, Raz I, , et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two doubleblind, placebo-controlled studies. Diabetes Obes Metab 2005;7(1):28-39.
  24. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25(2):515-29.
  25. Donelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obesityand Metabolism 2009;11:338-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies